Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, Michele Merli, Nicole Fabbri, Maria Elena Nizzoli, Matthew J Maurer, Vittoria Tarantino, Simone Ferrero, Sara Rattotti, Annalisa Talami, Roberta Murru, Arushi Khurana, Raphael Mwangi, Marina Deodato, Emanuele Cencini, Francesca Re, Carlo Visco, Andrew L Feldman, Brian K Link, Marcia Torresan Delamain, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés J M Ferreri, Caterina Cecilia Stelitano, Elsa Pennese, Thomas M Habermann, Luigi Marcheselli, Sunwoo Han, Isildinha M Reis, Marco Paulli, Izidore S Lossos, James R Cerhan, Stefano Luminari
BACKGROUND: Marginal zone lymphomas (MZL), comprised of three unique but related subtypes, lack a unifying prognostic score applicable to all the patients in need for systemic chemotherapy and/or immunotherapy. METHODS: Patients from the prospective NF10 study (NCT02904577) with newly diagnosed MZL and receiving frontline systemic therapy at diagnosis or after observation were used to train a prognostic model. The primary endpoint was progression-free survival (PFS) from start of treatment...
June 2024: EClinicalMedicine
#2
JOURNAL ARTICLE
Jacob D Soumerai, Catherine S Diefenbach, Deepa Jagadeesh, Adam Asch, Abhijeet Kumar, Michaela L Tsai, Thomas A Jandl, Izidore S Lossos, Vaishalee P Kenkre, Farrukh Awan, William Novotny, Jane Huang, Lu Miao, Prabhu Rajagopalan, Richard G Ghalie, Andrew D Zelenetz
The combination of the phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor zandelisib with the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib was hypothesized to be synergistic and prevent resistance to single-agent therapy. This phase 1 study (NCT02914938) included a dose-finding stage in patients with relapsed/refractory (R/R) B-cell malignancies (n = 20) and disease-specific expansion cohorts in follicular lymphoma (FL; n = 31) or mantle cell lymphoma (MCL; n = 19)...
March 19, 2024: British Journal of Haematology
#3
JOURNAL ARTICLE
James R Cerhan, Matthew J Maurer, Brian K Link, Andrew L Feldman, Thomas M Habermann, David L Jaye, W Richard Burack, Timothy J McDonnell, Francisco Vega, Jennifer R Chapman, Sergei Syrbu, Kiran R Vij, Giorgio Inghirami, John P Leonard, Leon Bernal-Mizrachi, Umar Farooq, Thomas E Witzig, George J Weiner, Yucai Wang, Juan P Alderuccio, Susan L Slager, Melissa C Larson, Shaun M Riska, Brianna J Gysbers, Julianne J Lunde, Tanner W Reicks, Amy A Ayers, Colin B O'Leary, Kathleen J Yost, Hongfang Liu, Grzegorz S Nowakowski, Jia Ruan, Dai Chihara, Jean L Koff, Carla Casulo, Carrie A Thompson, Jonathon B Cohen, Brad S Kahl, Loretta J Nastoupil, Izidore S Lossos, Jonathan W Friedberg, Peter Martin, Christopher R Flowers
To address the current and long-term unmet health needs of the growing population of non-Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18-99). Participants came from 49 US states and included 538 Black/African-Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents...
January 13, 2024: American Journal of Hematology
#4
JOURNAL ARTICLE
Tycel J Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S Lossos, Pier Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Ping Jiang, Peter Johnson
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell lymphomas. The phase 2 CITADEL-204 study (NCT03144674, EudraCT 2017-000970-12) assessed efficacy and safety of parsaclisib in Bruton tyrosine kinase (BTK) inhibitor-experienced (cohort 1) or BTK inhibitor-naive (cohort 2) patients with R/R marginal zone lymphoma (MZL). Patients aged ≥18 years with histologically confirmed R/R MZL, treated with ≥1 prior systemic therapy (including ≥1 anti-CD20 antibody) received parsaclisib 20 mg once daily for 8 weeks then 20 mg once weekly (weekly dosing group [WG]) or parsaclisib 20 mg once daily for 8 weeks then 2...
February 27, 2024: Blood Advances
#5
JOURNAL ARTICLE
Lihua E Budde, Adam J Olszewski, Sarit Assouline, Izidore S Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K Nakhoda, Stephen D Smith, Kathleen Dorritie, Ting Jia, Song Pham, Ling-Yuh Huw, Jing Jing, Hao Wu, Wahib S Ead, Iris To, Connie Lee Batlevi, Michael C Wei, Julio C Chavez
Relapsed/refractory aggressive large B cell lymphoma (LBCL) remains an area of unmet need. Here we report the primary analysis of a phase 1b/2 trial of outpatient mosunetuzumab (a CD20xCD3 T-cell-engaging bispecific antibody) plus polatuzumab vedotin (an anti-CD79B antibody-drug conjugate) in relapsed/refractory LBCL. The phase 2 component is a single arm of an ongoing multi-arm trial. The primary endpoint during dose expansion was independent review committee (IRC)-assessed best overall response rate. Secondary endpoints included investigator-assessed overall response rate, complete response, duration of response, progression-free survival and overall survival...
January 2024: Nature Medicine
#6
JOURNAL ARTICLE
Matthew J Maurer, Carla Casulo, Melissa C Larson, Thomas M Habermann, Izidore S Lossos, Yucai Wang, Loretta J Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin, Jonathon B Cohen, Brad S Kahl, W Richard Burack, Jean L Koff, Yong Mun, Anthony Masaquel, Mei Wu, Michael C Wei, Ashwini Shewade, Jia Li, James R Cerhan, Brian K Link, Christopher R Flowers
Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells. A recent pivotal phase I/II clinical trial (GO29781) demonstrated that mosunetuzumab induced an overall response rate of 80%, complete response rate of 60%, and a median progression-free survival of 17.9 months in patients with relapsed/refractory (r/r) follicular lymphoma (FL) following at least two prior lines of systemic therapy, including alkylator and anti-CD20 antibody-based therapy...
November 30, 2023: Haematologica
#7
JOURNAL ARTICLE
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, Muthiah Nachiappan, Salman Leslom, Brad S Kahl, Weiyun Z Ai, John Radford, Melhem Solh, Kirit M Ardeshna, Brian T Hess, Matthew A Lunning, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Izidore S Lossos, Paolo F Caimi, Sunwoo Han, Fei Yang, Russ A Kuker, Craig H Moskowitz
PURPOSE: Significant progress has occurred in developing quantitative PET/CT biomarkers in diffuse large B-cell lymphoma (DLBCL). Total metabolic tumor volume (MTV) is the most extensively studied, enabling assessment of FDG-avid tumor burden associated with outcomes. However, prior studies evaluated the outcome of cytotoxic chemotherapy or chimeric antigen receptor T-cell without data on recently approved FDA agents. Therefore, we aimed to assess the prognosis of PET/CT-biomarkers in patients treated with loncastuximab tesirine...
October 19, 2023: Clinical Cancer Research
#8
Marco Magistri, Lanie E Happ, Jeremy Ramdial, XiaoQing Lu, Vasileios Stathias, Kranthi Kunkalla, Nitin Agarwal, Xiaoyu Jiang, Stephan C Schürer, Sander R Dubovy, Jennifer R Chapman, Francisco Vega, Sandeep Dave, Izidore S Lossos
[This corrects the article DOI: 10.1158/2767-9764.CRC-21-0022.][This corrects the article DOI: 10.1158/2767-9764.CRC-21-0022.].
August 2023: Cancer Res Commun
#9
JOURNAL ARTICLE
Raphael E Steiner, Steven R Hwang, Arushi Khurana, Thomas M Habermann, Narendranath Epperla, Kaitlin Annunzio, Pamela Blair Allen, Katelin Baird, Darina Paulino, Juan Pablo Alderuccio, Izidore S Lossos, Kevin David, Andrew M Evens, Karan Pandya, Steven M Bair, Manali Kamdar, Sheeba Ba Aqeel, Pallawi Torka, Ryan Lynch, Stephen Smith, Lei Feng, Mansoor Noorani, Sairah Ahmed, Ranjit Nair, Francisco Vega, Susan Wu, Penny Fang, Chelsea C Pinnix, Jillian R Gunther, Bouthaina S Dabaja, Hun J Lee
In the pivotal study ECHELON-1, brentuximab vedotin (BV), doxorubicin, vinblastine, and dacarbazine (A + AVD) demonstrated superior efficacy compared with bleomycin + AVD for the treatment of advanced-stage classic Hodgkin lymphoma (cHL). However, there are minimal available data regarding the frequency of dose reductions or omission of BV during curative therapy and the potential impact on patient outcomes. In a real-world analysis, we retrospectively reviewed the characteristics and outcomes of 179 patients with stage III or IV cHL treated with frontline A + AVD from January 2010 to April 2022...
December 26, 2023: Blood Advances
#10
JOURNAL ARTICLE
Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, Philippe Armand, Tae Min Kim, Dok Hyun Yoon, Amitkumar Mehta, Richard Greil, Jason R Westin, Izidore S Lossos, Javier Munoz, Jason Sit, Michael C Wei, Annie Yang, Vivian Chen, Enkhtsetseg Purev, Donald L Yee, Ulrich Jaeger
Please note that the abstract has been provided separately as it is now over the word count due to the incorporation of reviewer suggestions.
August 15, 2023: Blood Advances
#11
JOURNAL ARTICLE
David A Russler-Germain, Kilannin Krysiak, Cody Ramirez, Matthew Mosior, Marcus P Watkins, Felicia Gomez, Zachary L Skidmore, Lee Trani, Feng Gao, Susan Geyer, Amanda F Cashen, Neha Mehta-Shah, Brad S Kahl, Nancy L Bartlett, Juan P Alderuccio, Izidore S Lossos, Sarah L Ondrejka, Eric D Hsi, Peter Martin, John P Leonard, Malachi Griffith, Obi L Griffith, Todd A Fehniger
Follicular lymphoma (FL) is clinically heterogeneous, with select patients tolerating extended watch-and-wait, whereas others require prompt treatment, suffer progression of disease within 24 months of treatment (POD24), and/or experience aggressive histologic transformation (t-FL). Because our understanding of the relationship between genetic alterations in FL and patient outcomes remains limited, we conducted a clinicogenomic analysis of 370 patients with FL or t-FL (from Cancer and Leukemia Group B/Alliance trials 50402/50701/50803, or real-world cohorts from Washington University School of Medicine, Cleveland Clinic, or University of Miami)...
September 26, 2023: Blood Advances
#12
REVIEW
Juan Pablo Alderuccio, Izidore S Lossos
INTRODUCTION: Extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid tissue is an indolent lymphoma originating from marginal zone B-cells and associated with chronic inflammation. EMZL demonstrates distinct genomic alterations according to the primary extranodal site of disease but commonly affects signaling pathways including NF-ĸB, B-cell receptor, and NOTCH. Treatment with radiation therapy is commonly implemented in localized diseases, and multiple agents are available for patients with advanced-stage diseases in need of therapy...
May 2023: Expert Review of Hematology
#13
JOURNAL ARTICLE
Juan Pablo Alderuccio, Isildinha M Reis, Jean L Koff, Melissa C Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M Habermann, Peter Martin, Jennifer R Chapman, Christopher Strouse, Brad S Kahl, Jonathon B Cohen, Jonathan W Friedberg, James R Cerhan, Christopher R Flowers, Izidore S Lossos
No abstract text is available yet for this article.
April 13, 2023: Blood
#14
JOURNAL ARTICLE
Chen Lossos, M Nadji, Izidore S Lossos, Jennifer R Chapman
We describe our recent experience of studying expression of immunoglobulin (Ig) heavy chain (IgG, IgM, and IgA) in lymphoid cells comprising a research set of formalin-fixed, paraffin-embedded human diffuse large B-cell lymphoma samples. We found that using typical clinical automated immunohistochemistry protocols and usual buffers as blocking agents, the extent of undesirable staining was extreme and impaired our ability to interpret heavy chain Ig expression by individual lymphoid cells. We were not able to optimize this with serial dilutions in antibody concentration or time of primary antibody exposure...
November 28, 2022: Applied Immunohistochemistry & Molecular Morphology: AIMM
#15
MULTICENTER STUDY
Brian T Hess, Anshu Giri, Yeonhee Park, Krina K Patel, Brian K Link, Grzegorz S Nowakowski, Seth M Maliske, Sonia Fortin, Julio C Chavez, Hayder Saeed, Brian T Hill, Alex V Mejia Garcia, Kami J Maddocks, Walter Hanel, Nina D Wagner-Johnston, Marcus R Messmer, Brad S Kahl, Marcus Watkins, Juan Pablo Alderuccio, Izidore S Lossos, Sunita Nathan, Victor M Orellana-Noia, Craig A Portell, Daniel J Landsburg, Emily C Ayers, Jorge J Castillo
Plasmablastic lymphoma (PBL) is a rare entity, commonly associated with immunosuppressed states such as human immunodeficiency virus (HIV) infection or solid organ transplant. The clinical course is characterized by high relapse rates and a poor prognosis, leading some clinicians to recommend aggressive frontline therapy. However, a specific review of limited stage (LS) PBL patients is not available to evaluate outcomes and justify treatment recommendations. We performed a retrospective review of LS PBL cases to provide insight into this rare disease...
February 2023: American Journal of Hematology
#16
JOURNAL ARTICLE
Russ A Kuker, David Lehmkuhl, Deukwoo Kwon, Weizhao Zhao, Izidore S Lossos, Craig H Moskowitz, Juan Pablo Alderuccio, Fei Yang
Metabolic tumor volume (MTV) is a robust prognostic biomarker in diffuse large B-cell lymphoma (DLBCL). The available semiautomatic software for calculating MTV requires manual input limiting its routine application in clinical research. Our objective was to develop a fully automated method (AM) for calculating MTV and to validate the method by comparing its results with those from two nuclear medicine (NM) readers. The automated method designed for this study employed a deep convolutional neural network to segment normal physiologic structures from the computed tomography (CT) scans that demonstrate intense avidity on positron emission tomography (PET) scans...
October 25, 2022: Cancers
#17
JOURNAL ARTICLE
Anas Younes, John M Burke, Bruce D Cheson, Catherine S Diefenbach, Silvia Ferrari, Uwe H Hahn, Eliza A Hawkes, Cyrus Khan, Izidore S Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G Nielsen, Gila Sellam, Jeff P Sharman
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) and is curative in ∼60% of patients. Atezolizumab is a humanized immunoglobulin G1 monoclonal antibody that targets programmed death-ligand 1 and has previously shown antitumor activity in several tumor types. In a phase 1b/2 trial (NCT02596971), we evaluated the safety and efficacy of atezolizumab in combination with R-CHOP (atezo-R-CHOP; for 6-8 cycles) in patients with previously untreated DLBCL...
April 25, 2023: Blood Advances
#18
JOURNAL ARTICLE
Ashish Patil, Steven H Swerdlow, Izidore S Lossos, Jennifer R Chapman
There has been a surge in COVID-19 vaccine-associated lymphadenopathy (LAD), including after the booster dose of vaccine. This can create diagnostic dilemmas in oncology patients as the relatively sudden LAD can mimic metastasis or cancer recurrence, at a risk of leading to additional but unnecessary anti-neoplastic therapy. Here we report the histopathologic features in a case of persistent LAD occurring in a patient with history of breast invasive ductal carcinoma which followed a COVID-19 vaccine booster...
September 13, 2022: Virchows Archiv: An International Journal of Pathology
#19
JOURNAL ARTICLE
Juan Pablo Alderuccio, Isildinha M Reis, Thomas M Habermann, Brian K Link, Catherine Thieblemont, Annarita Conconi, Melissa C Larson, Luciano Cascione, Wei Zhao, James R Cerhan, Emanuele Zucca, Izidore S Lossos
Extranodal marginal zone lymphoma (EMZL) is a heterogeneous disease with a subset of patients exhibiting a more aggressive course. We previously reported that EMZL with multiple mucosal sites (MMS) at diagnosis is characterized by shorter survival. To better recognize patients with different patterns of progression-free survival (PFS) we developed and validated a new prognostic index primarily based on patient's disease characteristics. We derived the "Revised mucosa-associated lymphoid tissue International Prognostic Index" (Revised MALT-IPI) in a large data set (n=397) by identifying candidate variables that showed highest prognostic association with PFS...
September 3, 2022: American Journal of Hematology
#20
JOURNAL ARTICLE
Juan Pablo Alderuccio, Thomas Habermann, Russ Kuker, Craig H Moskowitz, Andrew D Zelenetz, Izidore S Lossos
Marginal zone lymphoma (MZL) is commonly underrepresented in clinical trials collectively studying mostly nodal indolent lymphomas.In this manuscript we propose new inclusion and response criteria defined by MZL subtype and disease location for those with extranodal MZL. Progression of disease within 24 months is associated with poor outcomes in MZL and future studies should assess the efficacy of novel agents in this population.
August 28, 2022: American Journal of Hematology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
